Skip to main content
Erschienen in: Wiener klinisches Magazin 5-6/2022

13.10.2022 | Chirurgie

Chirurgische Therapie des Ösophaguskarzinoms – neue Technologien, moderne Konzepte

verfasst von: Prof. DDr. Thomas Schmidt, Dr. Benjamin Babic, Univ.-Prof. Dr. Christiane J. Bruns, Univ.-Prof. Dr. Hans F. Fuchs

Erschienen in: Wiener klinisches Magazin | Ausgabe 5-6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Ösophaguskarzinom wird in Deutschland meist in spezialisierten Zentren entsprechend den Leitlinien multimodal und interdisziplinär therapiert. In den kommenden Jahren wird die Zentralisierung der Ösophaguschirurgie in Deutschland durch die Festlegung neuer Mindestmengen weiter voranschreiten. Dieser Artikel soll neue Technologien für die chirurgische Therapie des Ösophaguskarzinoms und zudem aktuelle onkologische Konzepte aus der Sicht eines High-volume-Centers vorstellen.
Literatur
3.
Zurück zum Zitat Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB, SANO-study group (2021) Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 22(1):345. https://doi.org/10.1186/s13063-021-05274-wCrossRefPubMedPubMedCentral Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB, SANO-study group (2021) Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 22(1):345. https://​doi.​org/​10.​1186/​s13063-021-05274-wCrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Müller-Stich BP, Probst P, Nienhüser H, Fazeli S, Senft J, Kalkum E, Heger P, Warschkow R, Nickel F, Billeter AT, Grimminger PP, Gutschow C, Dabakuyo-Yonli TS, Piessen G, Paireder M, Schoppmann SF, van der Peet DL, Cuesta MA, van der Sluis P, van Hillegersberg R, Hölscher AH, Diener MK, Schmidt T (2021) Meta-analysis of randomized controlled trials and individual patient data comparing minimally invasive with open oesophagectomy for cancer. Br J Surg. https://doi.org/10.1093/bjs/znab278CrossRefPubMed Müller-Stich BP, Probst P, Nienhüser H, Fazeli S, Senft J, Kalkum E, Heger P, Warschkow R, Nickel F, Billeter AT, Grimminger PP, Gutschow C, Dabakuyo-Yonli TS, Piessen G, Paireder M, Schoppmann SF, van der Peet DL, Cuesta MA, van der Sluis P, van Hillegersberg R, Hölscher AH, Diener MK, Schmidt T (2021) Meta-analysis of randomized controlled trials and individual patient data comparing minimally invasive with open oesophagectomy for cancer. Br J Surg. https://​doi.​org/​10.​1093/​bjs/​znab278CrossRefPubMed
6.
Zurück zum Zitat Kuppusamy MK, Low DE, International Esodata Study Group (IESG) (2020) Evaluation of international contemporary operative outcomes and management trends associated with esophagectomy: a 4‑year study of 〉6000 patients using ECCG definitions and the Online Esodata database. Ann Surg. https://doi.org/10.1097/SLA.0000000000004309CrossRef Kuppusamy MK, Low DE, International Esodata Study Group (IESG) (2020) Evaluation of international contemporary operative outcomes and management trends associated with esophagectomy: a 4‑year study of 〉6000 patients using ECCG definitions and the Online Esodata database. Ann Surg. https://​doi.​org/​10.​1097/​SLA.​0000000000004309​CrossRef
7.
8.
Zurück zum Zitat Martinello N, Loshak H (2020) Experiences with and expectations of robotic surgical systems: a rapid qualitative review. Canadian Agency for Drugs and Technologies in Health, Ottawa (Internet) Martinello N, Loshak H (2020) Experiences with and expectations of robotic surgical systems: a rapid qualitative review. Canadian Agency for Drugs and Technologies in Health, Ottawa (Internet)
9.
Zurück zum Zitat Horgan S, Berger RA, Elli EF, Espat NJ (2003) Robotic-assisted minimally invasive transhiatal esophagectomy. Am Surg 69(7):624–626PubMed Horgan S, Berger RA, Elli EF, Espat NJ (2003) Robotic-assisted minimally invasive transhiatal esophagectomy. Am Surg 69(7):624–626PubMed
10.
Zurück zum Zitat Szold A, Bergamaschi R, Broeders I, Dankelman J, Forgione A, Langø T, Melzer A, Mintz Y, Morales-Conde S, Rhodes M, Satava R, Tang CN, Vilallonga R, European Association of Endoscopic Surgeons. (2015) European Association of Endoscopic Surgeons (EAES) consensus statement on the use of robotics in general surgery. Surg Endosc 29(2):253–288. https://doi.org/10.1007/s00464-014-3916-9CrossRefPubMed Szold A, Bergamaschi R, Broeders I, Dankelman J, Forgione A, Langø T, Melzer A, Mintz Y, Morales-Conde S, Rhodes M, Satava R, Tang CN, Vilallonga R, European Association of Endoscopic Surgeons. (2015) European Association of Endoscopic Surgeons (EAES) consensus statement on the use of robotics in general surgery. Surg Endosc 29(2):253–288. https://​doi.​org/​10.​1007/​s00464-014-3916-9CrossRefPubMed
11.
Zurück zum Zitat Fuchs HF, Collins JW, Babic B, DuCoin C, Meireles OR, Grimminger PP, Read M, Abbas A, Sallum R, Müller-Stich BP, Perez D, Biebl M, Egberts JH, van Hillegersberg R, Bruns CJ (2021) Robotic-assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer training curriculum—a worldwide Delphi consensus study. Dis Esophagus. https://doi.org/10.1093/dote/doab055CrossRefPubMed Fuchs HF, Collins JW, Babic B, DuCoin C, Meireles OR, Grimminger PP, Read M, Abbas A, Sallum R, Müller-Stich BP, Perez D, Biebl M, Egberts JH, van Hillegersberg R, Bruns CJ (2021) Robotic-assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer training curriculum—a worldwide Delphi consensus study. Dis Esophagus. https://​doi.​org/​10.​1093/​dote/​doab055CrossRefPubMed
12.
Zurück zum Zitat Datta RR, Dieplinger G, Wahba R, Kleinert R, Thomas M, Gebauer F, Schiffmann L, Stippel DL, Bruns CJ, Fuchs HF (2020) True single-port cholecystectomy with ICG cholangiography through a single 15-mm trocar using the new surgical platform “symphonX”: first human case study with a commercially available device. Surg Endosc 34(6):2722–2729. https://doi.org/10.1007/s00464-019-07229-4CrossRefPubMed Datta RR, Dieplinger G, Wahba R, Kleinert R, Thomas M, Gebauer F, Schiffmann L, Stippel DL, Bruns CJ, Fuchs HF (2020) True single-port cholecystectomy with ICG cholangiography through a single 15-mm trocar using the new surgical platform “symphonX”: first human case study with a commercially available device. Surg Endosc 34(6):2722–2729. https://​doi.​org/​10.​1007/​s00464-019-07229-4CrossRefPubMed
15.
Zurück zum Zitat Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017 Jan 12;541(7636):169–175. https://doi.org/10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061; PMCID: PMC5651175. Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017 Jan 12;541(7636):169–175. https://​doi.​org/​10.​1038/​nature20805. Epub 2017 Jan 4. PMID: 28052061; PMCID: PMC5651175.
16.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar BEJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/NEJMoa1112088CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar BEJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://​doi.​org/​10.​1056/​NEJMoa1112088CrossRefPubMed
17.
Zurück zum Zitat Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD, FLOT4-AIO Investigators (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1CrossRefPubMed Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD, FLOT4-AIO Investigators (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957. https://​doi.​org/​10.​1016/​S0140-6736(18)32557-1CrossRefPubMed
18.
Zurück zum Zitat Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR (2016) ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:503. https://doi.org/10.1186/s12885-016-2564-yCrossRefPubMedPubMedCentral Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR (2016) ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:503. https://​doi.​org/​10.​1186/​s12885-016-2564-yCrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators (2021) Adjuvant nivolumab in resected esophageal or Gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203. https://doi.org/10.1056/NEJMoa2032125CrossRefPubMed Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators (2021) Adjuvant nivolumab in resected esophageal or Gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203. https://​doi.​org/​10.​1056/​NEJMoa2032125CrossRefPubMed
21.
Zurück zum Zitat Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB, SANO-study group (2018) Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 18(1):142. https://doi.org/10.1186/s12885-018-4034-1CrossRefPubMedPubMedCentral Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB, SANO-study group (2018) Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 18(1):142. https://​doi.​org/​10.​1186/​s12885-018-4034-1CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB, SANO-study group (2021) Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 22(1):345. https://doi.org/10.1186/s13063-021-05274-wCrossRefPubMedPubMedCentral Eyck BM, van der Wilk BJ, Noordman BJ, Wijnhoven BPL, Lagarde SM, Hartgrink HH, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, van der Zaag ES, Spaander MCW, Valkema R, Lingsma HF, Steyerberg EW, van Lanschot JJB, SANO-study group (2021) Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer. Trials 22(1):345. https://​doi.​org/​10.​1186/​s13063-021-05274-wCrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, SANO study group (2018) Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 19(7):965–974. https://doi.org/10.1016/S1470-2045(18)30201-8CrossRefPubMed Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, SANO study group (2018) Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 19(7):965–974. https://​doi.​org/​10.​1016/​S1470-2045(18)30201-8CrossRefPubMed
24.
Zurück zum Zitat Zhang X, Eyck BM, Yang Y, Liu J, Chao YK, Hou MM, Hung TM, Pang Q, Yu ZT, Jiang H, Law S, Wong I, Lam KO, van der Wilk BJ, van der Gaast A, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB, Li Z (2020) Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. Bmc Cancer 20(1):194. https://doi.org/10.1186/s12885-020-6669-yCrossRefPubMedPubMedCentral Zhang X, Eyck BM, Yang Y, Liu J, Chao YK, Hou MM, Hung TM, Pang Q, Yu ZT, Jiang H, Law S, Wong I, Lam KO, van der Wilk BJ, van der Gaast A, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB, Li Z (2020) Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. Bmc Cancer 20(1):194. https://​doi.​org/​10.​1186/​s12885-020-6669-yCrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A (2018) Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer 21(2):303–314. https://doi.org/10.1007/s10120-017-0746-1CrossRefPubMed Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A (2018) Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer 21(2):303–314. https://​doi.​org/​10.​1007/​s10120-017-0746-1CrossRefPubMed
26.
Zurück zum Zitat Heger P, Blank S, Gooßen K, Nienhüser H, Diener MK, Ulrich A, Mihaljevic AL, Schmidt T (2019) Thoracoabdominal versus transhiatal surgical approaches for adenocarcinoma of the esophagogastric junction—a systematic review and meta-analysis. Langenbecks Arch Surg 404(1):103–113. https://doi.org/10.1007/s00423-018-1745-3CrossRefPubMed Heger P, Blank S, Gooßen K, Nienhüser H, Diener MK, Ulrich A, Mihaljevic AL, Schmidt T (2019) Thoracoabdominal versus transhiatal surgical approaches for adenocarcinoma of the esophagogastric junction—a systematic review and meta-analysis. Langenbecks Arch Surg 404(1):103–113. https://​doi.​org/​10.​1007/​s00423-018-1745-3CrossRefPubMed
27.
Zurück zum Zitat Leers JM, Knepper L, van der Veen A, Schröder W, Fuchs H, Schiller P, Hellmich M, Zettelmeyer U, Brosens LAA, Quaas A, Ruurda JP, van Hillegersberg R, Bruns CJ (2020) The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer 20(1):781. https://doi.org/10.1186/s12885-020-07152-1CrossRefPubMedPubMedCentral Leers JM, Knepper L, van der Veen A, Schröder W, Fuchs H, Schiller P, Hellmich M, Zettelmeyer U, Brosens LAA, Quaas A, Ruurda JP, van Hillegersberg R, Bruns CJ (2020) The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer 20(1):781. https://​doi.​org/​10.​1186/​s12885-020-07152-1CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Urbanski A, Babic B, Schröder W, Schiffmann L, Müller DT, Bruns CJ, Fuchs HF (2021) Neue Techniken und Trainingsmethoden für die roboterassistierte Chirurgie und Kosten-Nutzen-Bewertung anhand der Ivor-Lewis-Ösophagektomie [New techniques and training methods for robot-assisted surgery and cost-benefit analysis of Ivor Lewis esophagectomy. Chirurg 92(2):97–101. https://doi.org/10.1007/s00104-020-01317-1CrossRefPubMed Urbanski A, Babic B, Schröder W, Schiffmann L, Müller DT, Bruns CJ, Fuchs HF (2021) Neue Techniken und Trainingsmethoden für die roboterassistierte Chirurgie und Kosten-Nutzen-Bewertung anhand der Ivor-Lewis-Ösophagektomie [New techniques and training methods for robot-assisted surgery and cost-benefit analysis of Ivor Lewis esophagectomy. Chirurg 92(2):97–101. https://​doi.​org/​10.​1007/​s00104-020-01317-1CrossRefPubMed
30.
Zurück zum Zitat Berducci M, Fuchs HF, Omelanczuk P, Broderick RC, Harnsberger CR, Langert J, Nefa J, Jaureguiberry P, Gomez P, Miranda L, Jacobsen GR, Sandler BJ, Horgan S (2016) Phase II clinical experience and long-term follow-up using the next-generation single-incision platform FMX314. Surg Endosc 30(3):953–960. https://doi.org/10.1007/s00464-015-4319-2CrossRefPubMed Berducci M, Fuchs HF, Omelanczuk P, Broderick RC, Harnsberger CR, Langert J, Nefa J, Jaureguiberry P, Gomez P, Miranda L, Jacobsen GR, Sandler BJ, Horgan S (2016) Phase II clinical experience and long-term follow-up using the next-generation single-incision platform FMX314. Surg Endosc 30(3):953–960. https://​doi.​org/​10.​1007/​s00464-015-4319-2CrossRefPubMed
35.
Zurück zum Zitat Fuchs H (2020) Curriculum Robotische Chirurgie im oberen Gastrointestinaltrakt für Oberärzte und leitende Klinikchirurgen. Passion Chir 10(12):Artikel 04_02 Fuchs H (2020) Curriculum Robotische Chirurgie im oberen Gastrointestinaltrakt für Oberärzte und leitende Klinikchirurgen. Passion Chir 10(12):Artikel 04_02
Metadaten
Titel
Chirurgische Therapie des Ösophaguskarzinoms – neue Technologien, moderne Konzepte
verfasst von
Prof. DDr. Thomas Schmidt
Dr. Benjamin Babic
Univ.-Prof. Dr. Christiane J. Bruns
Univ.-Prof. Dr. Hans F. Fuchs
Publikationsdatum
13.10.2022
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 5-6/2022
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-022-00467-8

Weitere Artikel der Ausgabe 5-6/2022

Wiener klinisches Magazin 5-6/2022 Zur Ausgabe

panorama

panorama